Therapeutic drug monitoring -guided continuous infusion of Piperacillin/Tazobactam significantly improves pharmacokinetic target-attainment in critically ill patients: a retrospective analysis from four years of clinical experience

被引：0
|
作者：
Richter, D. C. [1 ]
Frey, O. [2 ]
Rohr, A. [2 ]
Roberts, J. A. [3 ,4 ,5 ,6 ]
Koeberer, A. [7 ]
Fuchs, Th [7 ]
Brenner, T. [1 ]
Lichtenstein, C. [1 ]
Weigand, M. A. [1 ]
Brinkmann, A. [7 ]
机构：
[1] Heidelberg Univ Hosp, Dept Anesthesiol, Heidelberg, Germany
[2] Heidenheim Hosp, Dept Clin Pharm, Heidenheim, Germany
[3] Univ Queensland, Ctr Clin Res, St Lucia, Qld 4072, Australia
[4] Univ Queensland, Sch Pharm, Ctr Translat Antiinfect Pharmacodynam, 20 Cornwall St, Woolloongabba, Qld 4102, Australia
[5] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[6] Royal Brisbane & Womens Hosp Herston, Herston, Qld 4029, Australia
[7] Heidenheim Hosp, Dept Anesthesiol, Heidenheim, Germany
来源：
INFECTION | 2019年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
010
引用
收藏
页码：S46 / S47
页数：2
相关论文
共 17 条
  • [1] Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience
    Richter, Daniel C.
    Frey, Otto
    Roehr, Anka
    Roberts, Jason A.
    Koeberer, Andreas
    Fuchs, Thomas
    Papadimas, Nikolaos
    Heinzel-Gutenbrunner, Monika
    Brenner, Thorsten
    Lichtenstern, Christoph
    Weigand, Markus A.
    Brinkmann, Alexander
    [J]. INFECTION, 2019, 47 (06) : 1001 - 1011
  • [2] Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience
    Daniel C. Richter
    Otto Frey
    Anka Röhr
    Jason A. Roberts
    Andreas Köberer
    Thomas Fuchs
    Nikolaos Papadimas
    Monika Heinzel-Gutenbrunner
    Thorsten Brenner
    Christoph Lichtenstern
    Markus A. Weigand
    Alexander Brinkmann
    [J]. Infection, 2019, 47 : 1001 - 1011
  • [3] Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020
    Drager, Sarah
    von Rotz, Matthias
    Labhardt, Niklaus D.
    Siegemund, Martin
    Rentsch, Katharina M.
    Osthoff, Michael
    Franzeck, Fabian C.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
  • [4] Continuous infusion of piperacillin and therapeutic drug monitoring for treatment of critically ill patients
    Koeberer, A.
    Frey, O. R.
    Papadimas, N.
    Fuchs, T.
    Roehr, A.
    Brinkmann, A.
    [J]. INFECTION, 2013, 41 : S54 - S54
  • [5] Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study
    Dhaese, Sofie A. M.
    Thooft, Alexander D. J.
    Farkas, Andras
    Lipman, Jeffrey
    Verstraete, Alain G.
    Stove, Veronique
    Roberts, Jason A.
    De Waele, Jan J.
    [J]. JOURNAL OF CRITICAL CARE, 2019, 52 : 75 - 79
  • [6] Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
    Hyun, Dong-gon
    Seo, Jarim
    Lee, Su Yeon
    Ahn, Jee Hwan
    Hong, Sang-Bum
    Lim, Chae-Man
    Koh, Younsuck
    Huh, Jin Won
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (11):
  • [7] Pharmacokinetic dose-approximation significantly increases pharmacokinetic target attainment during the first 24 h of treatment with continuously infused Piperacillin/Tazobactam in critically ill patients
    Richter, D. C.
    Frey, O.
    Roehr, A.
    Roberts, J. A.
    Koeberer, A.
    Fuchs, Th
    Brenner, T.
    Lichtenstein, C.
    Weigand, M. A.
    Brinkmann, A.
    [J]. INFECTION, 2019, 47 : S47 - S48
  • [8] Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study (vol 52, pg 75, 2019)
    Dhaese, Sofie A. M.
    Thooft, Alexander D. J.
    Farkas, Andras
    Lipman, Jeffrey
    Verstraete, Alain G.
    Stove, Veronique
    Roberts, Jason A.
    De Waele, Jan J.
    [J]. JOURNAL OF CRITICAL CARE, 2020, 56 : 325 - 325
  • [9] Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing
    Chiriac, Ute
    Richter, Daniel C.
    Frey, Otto R.
    Roehr, Anka C.
    Helbig, Sophia
    Preisenberger, Judit
    Hagel, Stefan
    Roberts, Jason A.
    Weigand, Markus A.
    Brinkmann, Alexander
    [J]. ANTIBIOTICS-BASEL, 2021, 10 (06):
  • [10] Clinical and economic benefit of the application of pharmacokinetic/ pharmacodynamic (PK/PD) modeling for the continuous infusion of piperacillin\tazobactam in critically ill patients with ventilator associated pneumonia
    Duszynska, W.
    Hurkacz, M.
    Kowalska-Krochmal, B.
    Switalska, M.
    Kaiser, T.
    Kuebler, A.
    [J]. INFECTION, 2009, 37 : 53 - 54
12